Literature DB >> 15890686

Inhibition of APC anticoagulant activity on oxidized phospholipid by anti-{beta}2-glycoprotein I monoclonal antibodies.

Omid Safa1, Charles T Esmon, Naomi L Esmon.   

Abstract

Activated protein C (APC) anticoagulant activity and the ability to be inhibited by auto-antibodies associated with thrombosis are strongly augmented by the presence of phosphatidylethanolamine (PE) and phospholipid oxidation. beta(2)-glycoprotein I (beta(2)-GPI) is a major antigen for antiphospholipid antibodies present in patients with the antiphospholipid syndrome. We therefore investigated whether anti-beta(2)-GPI monoclonal antibodies (mAbs) could inhibit APC with similar membrane specificity. Five mouse mAbs that reacted with different epitopes on beta(2)-GPI were examined. Each inhibited the PE-, phospholipid oxidation-dependent enhancement of APC anticoagulant activity and required antibody divalency. A chimeric APC that retains anticoagulant activity but is relatively unaffected by protein S, PE, or oxidation was not inhibited by the antibodies. In purified systems, anti-beta(2)-GPI mAb inhibition of factor Va inactivation was greater in the presence of protein S and required beta(2)-GPI. Surprisingly, although the mAbs did increase beta(2)-GPI affinity for membranes, PE and oxidation had little influence on the affinity of the beta(2)-GPI antibody complex for the membrane vesicles. We conclude that antibodies to beta(2)-GPI inhibit APC function specifically and contribute to a hypercoaguable state by disrupting specific protein-protein interactions induced by oxidation of PE-containing membranes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15890686      PMCID: PMC1895229          DOI: 10.1182/blood-2005-01-0404

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

1.  Anti-beta2 glycoprotein I (beta2GPI) autoantibodies recognize an epitope on the first domain of beta2GPI.

Authors:  G M Iverson; E J Victoria; D M Marquis
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

2.  Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant.

Authors:  E Marciniak; E H Romond
Journal:  Blood       Date:  1989-11-15       Impact factor: 22.113

3.  The epitopes for some antiphospholipid antibodies are adducts of oxidized phospholipid and beta2 glycoprotein 1 (and other proteins).

Authors:  S Hörkkö; E Miller; D W Branch; W Palinski; J L Witztum
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-16       Impact factor: 11.205

4.  The effect of membrane composition on the hemostatic balance.

Authors:  M D Smirnov; D A Ford; C T Esmon; N L Esmon
Journal:  Biochemistry       Date:  1999-03-23       Impact factor: 3.162

5.  Lipid oxidation enhances the function of activated protein C.

Authors:  O Safa; K Hensley; M D Smirnov; C T Esmon; N L Esmon
Journal:  J Biol Chem       Date:  2000-10-27       Impact factor: 5.157

6.  Association between the prevalence of antibodies to beta(2)-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications.

Authors:  J Nojima; H Kuratsune; E Suehisa; Y Futsukaichi; H Yamanishi; T Machii; Y Iwatani; Y Kanakura
Journal:  Clin Chem       Date:  2001-06       Impact factor: 8.327

7.  beta 2-Glycoprotein I modulates the anticoagulant activity of activated protein C on the phospholipid surface.

Authors:  T Mori; H Takeya; J Nishioka; E C Gabazza; K Suzuki
Journal:  Thromb Haemost       Date:  1996-01       Impact factor: 5.249

8.  Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome.

Authors:  R Schwarzenbacher; K Zeth; K Diederichs; A Gries; G M Kostner; P Laggner; R Prassl
Journal:  EMBO J       Date:  1999-11-15       Impact factor: 11.598

9.  A chimeric protein C containing the prothrombin Gla domain exhibits increased anticoagulant activity and altered phospholipid specificity.

Authors:  M D Smirnov; O Safa; L Regan; T Mather; D J Stearns-Kurosawa; S Kurosawa; A R Rezaie; N L Esmon; C T Esmon
Journal:  J Biol Chem       Date:  1998-04-10       Impact factor: 5.157

10.  beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome.

Authors:  H Bas de Laat; Ronald H W M Derksen; Rolf T Urbanus; Mark Roest; Philip G de Groot
Journal:  Blood       Date:  2004-08-17       Impact factor: 22.113

View more
  3 in total

Review 1.  Thrombolysis in antiphospholipid syndrome: current hematologic perspectives.

Authors:  René Y McNall-Knapp
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

2.  β₂-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model.

Authors:  Ariela Arad; Valerie Proulle; Richard A Furie; Barbara C Furie; Bruce Furie
Journal:  Blood       Date:  2011-01-18       Impact factor: 22.113

Review 3.  The enigmas of the lupus anticoagulant: mechanisms, diagnosis, and management.

Authors:  Richard A Marlar; Sanam Husain
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.